Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01366612 | Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation(FLUBUTBI) | terminated | Phase 3 | 53 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)(STIMULUS-MDS2) | terminated | Phase 3 | 530 | Novartis PharmaceuticalsINDUSTRY |
| 36 |
| Jan 13, 2026 |
| clinicaltrials |
| NCT03016130 | Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | terminated | Phase 3 | 217 | University of FloridaOTHER | 1 | Apr 7, 2025 | clinicaltrials |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS(THRIVE) | terminated | Phase 2 / Phase 3 | 1 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | terminated | Phase 3 | 52 | Goethe UniversityOTHER | 2 | Feb 16, 2023 | clinicaltrials |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)(CATHY) | terminated | Phase 3 | 11 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer(HATCY) | terminated | Phase 3 | 63 | Kiadis PharmaINDUSTRY | 13 | May 24, 2022 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT00176839 | Stem Cell Transplantation for Hematological Malignancies | terminated | Phase 2 / Phase 3 | 11 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00324324 | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant | terminated | Phase 3 | 240 | OHSU Knight Cancer InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01749111 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis(CICLODECH) | terminated | Phase 3 | 3 | Hospital Israelita Albert EinsteinOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00109538 | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | terminated | Phase 3 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 1, 2015 | clinicaltrials |
| NCT01203228 | Dose-reduced Versus Standard Conditioning in MDS/sAML(RICMAC) | terminated | Phase 3 | 129 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Apr 3, 2015 | clinicaltrials |
| NCT00306332 | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 3 | 250 | Radboud University Medical CenterOTHER | 1 | Aug 18, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Apr 3, 2026source: clinicaltrials